Stem cell therapy for liver fibrosis in chronic cases

Stem Cell Therapy for Liver Fibrosis in Chronic Cases

Liver fibrosis is a chronic and progressive condition characterized by the excessive deposition of extracellular matrix (ECM) in response to chronic liver injury. It can lead to cirrhosis and end-stage liver disease, necessitating liver transplantation. Stem cell therapy has emerged as a promising therapeutic approach for liver fibrosis, ofreciendo el potencial para la modificación y regeneración de enfermedades.

Etiology and Pathogenesis of Liver Fibrosis

Liver fibrosis is caused by various chronic liver diseases, incluyendo hepatitis viral, enfermedad del hígado graso no alcohólico (NAFLD), and autoimmune hepatitis. Hepatic stellate cells (HSC) play a central role in the fibrotic process. En respuesta a una lesión hepática, HSCs become activated and differentiate into myofibroblasts, which produce excessive ECM components, conduciendo a la fibrosis.

Papel de las células madre en la regeneración del hígado

Stem cells have the capacity for self-renewal and differentiation into various cell types. en el higado, stem cells are present in the canals of Hering and the bone marrow. These cells can differentiate into hepatocytes and cholangiocytes, las células funcionales del hígado, contribuyendo a la regeneración del hígado.

Preclinical Models of Liver Fibrosis and Stem Cell Therapy

Animal models of liver fibrosis have been used to evaluate the therapeutic potential of stem cell therapy. Studies have shown that bone marrow-derived stem cells (BMSC) can migrate to the injured liver, differentiate into hepatocytes and cholangiocytes, y atenuar la fibrosis. BMSCs have also been found to inhibit HSC activation and promote ECM degradation.